Bio-Rad Laboratories, Inc. $BIO Shares Purchased by BNP Paribas Financial Markets

BNP Paribas Financial Markets increased its stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 2,098.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 72,555 shares of the medical research company’s stock after purchasing an additional 69,254 shares during the quarter. BNP Paribas Financial Markets owned 0.27% of Bio-Rad Laboratories worth $21,983,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Royal Bank of Canada grew its holdings in shares of Bio-Rad Laboratories by 25.2% during the first quarter. Royal Bank of Canada now owns 30,310 shares of the medical research company’s stock worth $7,382,000 after purchasing an additional 6,100 shares during the last quarter. Goldman Sachs Group Inc. boosted its stake in shares of Bio-Rad Laboratories by 45.6% during the first quarter. Goldman Sachs Group Inc. now owns 105,006 shares of the medical research company’s stock worth $25,575,000 after buying an additional 32,874 shares during the period. Empowered Funds LLC raised its holdings in Bio-Rad Laboratories by 14.8% during the first quarter. Empowered Funds LLC now owns 1,547 shares of the medical research company’s stock worth $377,000 after purchasing an additional 199 shares in the last quarter. Jane Street Group LLC raised its holdings in Bio-Rad Laboratories by 95.3% during the first quarter. Jane Street Group LLC now owns 37,383 shares of the medical research company’s stock worth $9,105,000 after purchasing an additional 18,239 shares in the last quarter. Finally, Cetera Investment Advisers boosted its stake in shares of Bio-Rad Laboratories by 13.5% during the 2nd quarter. Cetera Investment Advisers now owns 2,192 shares of the medical research company’s stock worth $529,000 after acquiring an additional 260 shares in the last quarter. 65.24% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

BIO has been the topic of a number of research analyst reports. Weiss Ratings downgraded Bio-Rad Laboratories from a “sell (d+)” rating to a “sell (d)” rating in a research report on Wednesday, May 6th. Royal Bank Of Canada started coverage on Bio-Rad Laboratories in a research report on Friday, May 15th. They set an “outperform” rating and a $320.00 target price on the stock. Wells Fargo & Company lowered their price target on shares of Bio-Rad Laboratories from $320.00 to $290.00 and set an “equal weight” rating on the stock in a research report on Friday, May 1st. Wall Street Zen lowered shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research report on Saturday, February 14th. Finally, Citigroup lowered shares of Bio-Rad Laboratories from a “buy” rating to a “neutral” rating and lowered their price target for the company from $375.00 to $300.00 in a research report on Tuesday, April 7th. One research analyst has rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $303.33.

Bio-Rad Laboratories Trading Down 4.4%

NYSE BIO opened at $294.01 on Friday. The company’s fifty day simple moving average is $282.12 and its 200-day simple moving average is $291.70. Bio-Rad Laboratories, Inc. has a 52 week low of $219.42 and a 52 week high of $343.12. The company has a current ratio of 3.21, a quick ratio of 2.37 and a debt-to-equity ratio of 0.12. The stock has a market cap of $7.87 billion, a P/E ratio of 48.44 and a beta of 1.08.

Bio-Rad Laboratories (NYSE:BIO) last posted its earnings results on Thursday, April 30th. The medical research company reported $1.89 EPS for the quarter, missing analysts’ consensus estimates of $1.97 by ($0.08). The firm had revenue of $592.10 million for the quarter, compared to analyst estimates of $589.91 million. Bio-Rad Laboratories had a return on equity of 3.56% and a net margin of 6.52%.The company’s revenue for the quarter was up 1.1% on a year-over-year basis. During the same period in the previous year, the firm posted $2.54 earnings per share. Equities research analysts predict that Bio-Rad Laboratories, Inc. will post 9.42 EPS for the current fiscal year.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc is a global provider of life science research and clinical diagnostic products. The company operates through two primary business segments: Life Science and Clinical Diagnostics. Within the Life Science segment, Bio-Rad offers instruments, reagents and consumables for protein analysis, cell biology, gene expression and other molecular biology applications. The Clinical Diagnostics segment supplies quality control products, blood-typing reagents and instruments, and molecular diagnostic assays used in blood screening, infectious disease testing and routine clinical laboratories.

Founded in 1952 by David and Alice Schwartz and headquartered in Hercules, California, Bio-Rad has grown its footprint across the Americas, Europe, Asia-Pacific and other regions.